Compare Heron Therapeutics Inc (HRTX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Sirius XM Holdings Inc — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Sirius XM Holdings Inc trades at $28.23 (market cap $9.70B). The key difference: Sirius XM Holdings Inc is far larger — about 157.8× Heron Therapeutics Inc's market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SIRI | |
|---|---|---|
Market Cap | $61.47M | $9.70B |
Sector | Health | Media |
52-Week High | $1.49 | $32.59 |
52-Week Low | $0.32 | $19.92 |
Enterprise Value | $168.21M | $18.98B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
SIRI trades at $28.78, down 3.78% today, reflecting a bearish technical signal amid mixed earnings. The stock shows modest revenue growth and strong cash flow, with a P/E of 11.56 and P/B of 0.81 indicating potential undervaluation. Recent Q2 2026 earnings missed estimates, but the company raised full-year guidance, highlighting stable subscriber metrics and a dividend payout.
The outlook is cautiously optimistic, supported by analyst consensus of $33.17 price target and 58% buy ratings. Key risks include competitive pressures in satellite radio and high debt levels, though declining leverage and share buybacks offer upside. Investors should weigh stable cash generation against growth challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
